OPC-64005

OPC-64005 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), or "triple reuptake inhibitor" (TRI), which is under development for the treatment of major depressive disorder.^[1][2][3] It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD), but development for this indication was discontinued.^[1][4] It is taken by mouth.^[1]

OPC-64005

Clinical data
Other names	OPC64005
Routes of administration	Oral[1]
Drug class	Serotonin–norepinephrine–dopamine reuptake inhibitor (triple reuptake inhibitor)[1]

As of December 2022, OPC-64005 is in phase 2 clinical trials for major depressive disorder.^[1][2] It reached phase 2 clinical trials for ADHD prior to the discontinuation of its development for this use.^[1] It completed a phase 2 clinical trial for ADHD comparing it with placebo and atomoxetine, but the results of this trial were not disclosed.^[5] The drug is under development by Otsuka Pharmaceutical.^[1][2] It is a small molecule, but its chemical structure does not appear to have been disclosed.^[1][2]